Loading exclusive…
$IVDA: Q2 Earnings Preview — AI Vision Partnerships vs. Micro-Cap Volatility
Iveda Solutions reports Q2 Jun/2026 results; focus on revenue traction from GlobalMed and Primion deals against a backdrop of extreme micro-cap volatility.
Key Points
- No consensus EPS; focus on revenue growth and gross margin.
- Recent partnerships with GlobalMed and Primion provide commercial validation.
- EU AI Act readiness positions $IVDA for potential market share gains.
- Micro-cap volatility implies high sensitivity to any surprise.
What To Watch
- Q2 Revenue vs. Q1 and YoY growth.
- Management commentary on contract values and deployment timelines.
- Any new guidance or forward-looking statements on profitability.
- Post-print volume and price action for sentiment cues.